Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the depth of response for patients when investigating axitinib (Inlyta) and pembrolizumab (Keytruda) over sunitinib (Sutent) in the updated analysis of KEYNOTE-426 presented at the 2020 ASCO Virtual Scientific Program.
An exploratory analysis that we performed was looking at patients who survived to 6 months and assessing what their documented response was during that 6-month period. We didn’t just look at resist response, we looked at depth of response, so the percent shrinkage of target lesions. We put them into categories based on their depth of response. What we saw is that in a plus p, the deeper the response, the more the percentage of shrinkage in the target lesions, the better the overall survival. This relationship was pretty consistent across all the categories we looked at. This relationship did not interestingly hold true in the sunitinib arm, where depth of response did not seem to be as predictive of long-term outcome. In summary, we’re very pleased to report updated analysis of KEYNOTE-426. Since overall survival long-term is what we’re looking to achieve in this group of patients, we hope to continue to provide updates annually, certainly out to 5 years. I’m really interested in the 10-year update of this, sort of looking out into the future. Hopefully, we will show that some patients maintain durable responses in even treatment-free survival after treatment with axi pembro in the front-line.